Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01696734 · ClinicalTrials.gov registry record · Phase 3

Domperidone in Treating Patients With Gastrointestinal Disorders

A Phase 3 study of Gastroparesis and Gastroesophageal Reflux Disease, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 3
Development phase
200
Enrollment target
1
Study location

NCT01696734: Recruiting Phase 3 study of Gastroparesis and Gastroesophageal Reflux Disease, sponsored by M.D. Anderson Cancer Center.

NCT01696734 is a Phase 3 study of Gastroparesis and Gastroesophageal Reflux Disease that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 200 participants, below the 298-participant average among 44 other Gastroparesis trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01696734, a Phase 3 study of Gastroparesis and Gastroesophageal Reflux Disease, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 3
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

This phase III trial studies how well domperidone works in treating patients with gastrointestinal disorders. Domperidone may help control chronic gastrointestinal disorders and their symptoms, such as pain, bloating, and nausea and vomiting, by stimulating contraction of the stomach to increase its ability to empty itself of food.

Primary Outcome

Scale ranges from "0" meaning "None" to "5" meaning "Very Severe". Patients will be classified as either "new" or "continuing" at the baseline visit. A new patient will have a "response" if he/she has a 25% reduction in GCSI at 8 weeks. A continuing patient will already have early benefit to treatment so will have a "response" if the GCSI score does not increase more than 20% over baseline at 8 weeks. Summary statistics including number (n), mean, standard deviation, median, minimum, and maximu

Conditions Studied

Gastroparesis Gastroesophageal Reflux Disease Dyspepsia Heartburn Nausea and Vomiting Esophagitis Digestive System Disorder

Interventions

  • OTHER Questionnaire Administration
  • DRUG Domperidone

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2012-10-23
Est. Completion 2027-10-31
Phase Phase 3
M.D. Anderson Cancer Center

2,692 total trials

What NCT01696734 shows while recruiting

NCT01696734 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 298-participant average among 44 other Gastroparesis trials with a reported enrollment target (33% lower).

The record links to 7 conditions, with Gastroparesis appearing as the primary indexed condition, and to 2 interventions - of which Questionnaire Administration is the first listed.

NCT01696734 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT01696734 about?

NCT01696734 is a clinical study titled "Domperidone in Treating Patients With Gastrointestinal Disorders". This phase III trial studies how well domperidone works in treating patients with gastrointestinal disorders. Domperidone may help control chronic gastrointestinal disorders and their symptoms, such as pain, bloating, and nausea and vomiting, by stimulating contraction of the stomach to increase its...

What is the current status of trial NCT01696734?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2012-10-23. Estimated completion is 2027-10-31.

What conditions does trial NCT01696734 study?

This clinical trial studies the following conditions: Gastroparesis, Gastroesophageal Reflux Disease, Dyspepsia, Heartburn, Nausea and Vomiting.

What interventions are being tested in trial NCT01696734?

The interventions under investigation include: Questionnaire Administration (OTHER), Domperidone (DRUG).

Who is sponsoring clinical trial NCT01696734?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01696734 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastroparesis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01696734's enrollment target sits among peer trials

200 12th of 44 higher than 33 of 44 other Gastroparesis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gastroparesis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT01696734

Source: ClinicalTrials.gov NCT01696734, the US trial registry maintained by the National Library of Medicine. NCT01696734 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.